DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (“DTS”). According to the update, the results showed a marked reduction in the percentage of high blood glucose readings and in the average blood glucose readings in adults over the age of 65 years using Dario’s digital therapeutics platform (“Dario DTx”). “We believe that Dario’s DTx platform plays a role in driving behavioral modification and enhances adherence to diabetes and other chronic condition management in older adults,” said Yifat Hershcovitz, Ph.D., scientific and clinical director at DarioHealth. “The results show that the platform can significantly reduce the percentage of high blood glucose ratios and may facilitate significant improvement in clinical outcomes, leading to better health outcomes for older individuals with diabetes.”
To view the full press release, visit https://ibn.fm/eF3tb
About DarioHealth Corp.
DarioHealth is a leading, global digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its consumer-centric MyDario(TM) mobile app is loved by tens of thousands of members worldwide. DarioHealth is rapidly moving into new geographic markets to meet the needs of additional chronic conditions, using a performance-based approach to improve members’ management of chronic disease. To learn more about the company and its digital health solutions, visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.